Archive
Past newsletters of MDDR.
Loading the archive
Past newsletters of MDDR.
Past newsletters of MDDR.
Sunday, 20 September 2026
The US Food and Drug Administration has approved Fayuvi, the first gene therapy for the rare, progressive neurological condition Sanfilippo
Saturday, 19 September 2026
NSW passed reforms that will exempt eligible medicinal cannabis patients from drug-presence offences when driving with THC in their system,
Friday, 18 September 2026
Australia’s first Endometriosis Management Plan has launched to support consistent, evidence-based shared care for people with endometriosis
Thursday, 17 September 2026
AHPRA has issued guidance for prescribing off-label or unapproved medicines and medicines intended for compounding amid concerns about high-
Wednesday, 16 September 2026
The syphilis diagnosis rate among Australian women rose 167% over the past decade, according to new Kirby Institute analysis. Australia reco
Tuesday, 15 September 2026
A patient was hospitalised with uncontrolled vomiting and a torn oesophagus after using a counterfeit weight-loss peptide sold as retatrutid
Monday, 14 September 2026
Centric Compounding voluntarily recalled six lots of injectable products nationwide in the US after finding elevated endotoxin levels in the
Sunday, 13 September 2026
Proposed MBS simplification risks reducing the visibility and structure of women’s health care, according to commentary by Dr April Armstron
Saturday, 12 September 2026
Australian GP requests for anti-Müllerian hormone (AMH) tests increased more than 13-fold from 2011 to 2021, despite researchers concluding
Friday, 11 September 2026
The Federal Government is consulting on measures to curb what it deems ‘excessive’ specialist fees, including stronger bulk-billing incentiv